Glomerular disease related to anti-VEGF therapy

Kidney International

Volumn 74, Issue 11, 2008, Pages 1487-1491

  Stokes, M Barry ^a   Erazo, Maria C ^b   D'Agati, Vivette D ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NEW JERSEY NEUROSCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATORVASTATIN; BEVACIZUMAB; ENALAPRIL; FLUOROURACIL; FUROSEMIDE; HAPTOGLOBIN; LACTATE DEHYDROGENASE; METOLAZONE; PACLITAXEL; PAMIDRONIC ACID;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; CASE REPORT; CREATININE BLOOD LEVEL; DRUG DOSE INCREASE; DYSPNEA; FEMALE; GLOMERULOPATHY; HEMATOCRIT; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY FAILURE; LEG EDEMA; LEUKOCYTE COUNT; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTE COUNT; WEAKNESS;

ANTIBODIES, MONOCLONAL; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 56549115248     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.256     Document Type: Article

References (19)

1. Duda DG, Batchelor TT, Willett CG et al. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 2007; 13: 223-230.
2. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
3. Izzedine H, Rixe O, Billemont B et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007; 50: 203-218.
4. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69(Suppl 3): 25-33.
5. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
6. Frangie C, Lefaucheur C, Medioni J et al. Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007; 8: 177-178.
7. Izzedine H, Brocheriou I, Deray G et al. Thrombotic microangiopathy and anti-VEGF agents. Nephrol Dial Transplant 2007; 22: 1481-1482.
8. Roncone D, Satoskar A, Nadasdy T et al. Proteinuria in a patient receiving anti-VEGF therapy for metastatic renal cell carcinoma. Nat Clin Pract Nephrol 2007; 3: 287-293.
9. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
10. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
11. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29.
12. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172.
13. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65: 2003-2017.
14. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF - a signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol 2007; 106: p32-p37.
15. Eremina V, Sood M, Haigh J et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716.
16. Shimizu A, Masuda Y, Mori T et al. Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 2004; 15: 2655-2665.
17. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
18. Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33: 658-666.
19. Nasr SH, Markowitz GS, Sentman RL et al. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney Int 2006; 69: 1276-1280.